期刊文献+

不同预处理方案自体非清髓性造血干细胞移植治疗系统性红斑狼疮的临床观察

Clinical report on nonmyeloablative autologous peripheral blood stem cell transplantation for systemiclupus erythematosus by using different conditioning regimens
原文传递
导出
摘要 目的比较2种不同预处理方案行非清髓性自体外周血造血干细胞移植(NAST)治疗系统性红斑狼疮(SLE)的疗效及安全性。方法组一为阿糖胞苷(200mg·kg^-1·d^-1,-2--1d)+环磷酰胺(40mg·kg^-1·d^-1,-2--1d)。组二为抗胸腺细胞球蛋白(30mg·kg^-1·d^-1·,-5--3d)+环磷酰胺(40mg·kg^-1·d^-1,-2--1d)。评价患者移植前后免疫指标的变化、造血重建的情况及并发症。应用配对t检验,比较2组的白细胞、中性粒细胞、血小板恢复的时间。结果8例患者均成功植入。组一和组二各4例外周血白细胞〉10×10^9]L、中性粒细胞〉0.5×10^9/L、血小板〉100×10^9/L及血红蛋白〉120g/L的平均时间分别为[(7.2±1.3)、(8.0±1.5)、(10.5±12.4)、(22.1±2.3)d]和[(10.4±2.1)、(12.0±1.9)、(19.3±2.1)、(28.1±2.4)d],差异有统计学意义(氏0.02)。6例抗核抗体、抗双链DNA(dsDNA)抗体于移植后30。90d转阴,余2例分别于15个月和18个月后转阴。移植前明显降低的CD4+及CD4+/CD8+比值移植后逐渐恢复正常,2组差异无统计学意义。结论从免疫重建来看,是否使用ATG并没有明显差别。从安全性及造血重建考虑,我们推荐用阿糖胞苷+环磷酰胺替代含有ATG的方案进行预处理。 Objective To compare the clinical efficacy and safety of two different conditioning regimens in nonmyeloablative autologous peripheral blood stern cell transplantation (NAST) for the treatment of systemic lupus erythematosus (SLE). Methods Different conditioning regimens were used in two groups: cytarabin combined cyclophosphamide in group 1 and ATG combined cyclophosphamide in group 2. Different recovery time of leucocytes, neutrophils and platelets in the two groups were compared. Statistical analysis were carried out by paired t-test. Results The mean time for peripheral leucocytes reaching 1.0×10……9/L, neutrophils getting up to 0.5×10^9/L, platelet raising to 100×10^9/L and hemoglobin rising to 120 g/L in group 1 were [(7.2+1.3), (8.0±1.5), (10.5±1.4), (22.1±2.3)days] and [(10.4±2.1), (12.0±1.9), (19.3±2.1), (28.1± 2.4) ] days in group 2. The difference was statistically significant (P〈0.01). (P〈0.01) cell count and the ratio of CD4+/CD8+ of pre- and pro-NAST was changed. No significant differences were observed in the two groups. Conclusion For the sake of safety and hematopoietic reconstitution, we recommend cytarabin combined cvclophosphamide as the preferred conditioning regimen.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2012年第8期527-531,共5页 Chinese Journal of Rheumatology
基金 广东省珠海市科技局科技计划项目(PC20041041)
关键词 红斑狼疮 系统性 干细胞移植 移植预处理 Lupus erythematosus, systemic Stem cell eransplantation Transplantation condi-tioning
  • 相关文献

参考文献7

  • 1Marmont AM, VanLint MT, Gualandi F, et al. Autologous mar- row stem cell transplan-tation for severe systemic lupus erythe- matosus of long duration. Lupus, 1997, 6: 545-548.
  • 2Auletta JJ, Lazarus HM. Immune restoration following hematopoi- etic stem cell transplantation: an evolving target. Bone Marrow Transplant, 2005, 35: 835-857.
  • 3Burt PK, Pope R, Schroeder J, et al. Hematopoietic stem cell transplantation of autoimmune disease. Arthritis Rheum, 1998, 41 : S241.
  • 4Tyndall A, Gratwohi A. Blood and marrow stem cell transplants in auto-immune diseas: a consenses report written on behalf of the European League against Rheumatism (EULAR) and European Group for Blood and Marrow Transplantantion (EBMT). Bone Marrow Transplantation, 1997, 19: 643-645.
  • 5Jantunen E, Myllykangas-Luoiyarvi R. Stem cell transplantation for treatment of severe autoimmune disease: current status and future perspectives. Bone Marrow Transplantation, 2000, 25 : 355-356.
  • 6Traynor AE, Barr WG, Rosa RM, et al. Hematopoietic stern cell transplantation for severe and refractory lupus: analysis after five years and fifteen patients. Arthritis Rheum, 2002, 46: 2917- 2923.
  • 7Statkute L, Traynor A, 0yanla Y, et al. Anfiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood, 2005, 106: 2700-2709.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部